As shown in Figure 7, high mean expression of JAM-A, HER2 and FOXA1 mRNA in HER2-positive breast cancer patients (where the best cutoff between high and low expression was auto-selected by the online tool) was associated with significantly poorer distant metastasis-free survival (DMFS; Figure 7A, upper quartile survival of 25.8 months versus 53.45 months for patients with low combined expression) and recurrence-free survival (RFS; Figure 7D, upper quartile survival of 29.33 months versus 38.57 months for patients with low combined expression). This evidence concerns the gene FOXA1 and breast carcinoma.